COX2 inhibition in the treatment of COVID-19: Review of literature to propose repositioning of celecoxib for randomized controlled studies

Creative Commons License

Baghaki S., YALÇIN C. E., Baghaki H. S., Aydin S. Y., Daghan B., Yavuz E.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, cilt.101, ss.29-32, 2020 (SCI-Expanded, Scopus) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 101
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.ijid.2020.09.1466
  • Dergi Adı: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Sayfa Sayıları: ss.29-32
  • Anahtar Kelimeler: COX2, COVID-19, Immunomodulation, Coronavirus, Celecoxib, EPITHELIAL-MESENCHYMAL TRANSITION, CORONAVIRUS, HYDROXYCHLOROQUINE, CYCLOOXYGENASE-2, INVOLVEMENT, FIBROSIS, PROTEIN
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

Coronavirus-triggered pulmonary and systemic disease, i.e. systemic inflammatory response to virally triggered lung injury, named COVID-19, and ongoing discussions on refining immunomodulation in COVID-19 without COX2 inhibition prompted us to search the related literature to show a potential target (COX2) and a weapon (celecoxib). The concept of selectively targeting COX2 and closely related cascades might be worth trying in the treatment of COVID-19 given the substantial amount of data showing that COX2, p38 MAPK, IL-1b, IL-6 and TGF-beta play pivotal roles in coronavirus-related cell death, cytokine storm and pulmonary interstitial fibrosis. Considering the lack of definitive treatment and importance of immunomodulation in COVID-19, COX2 inhibition might be a valuable adjunct to still-evolving treatment strategies. Celecoxib has properties that should be evaluated in randomized controlled studies and is also available for off-label use. (C) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.